title: Update on TNF Inhibitors in Dermatology.
abstract: Emerging data describe new potential indications for tumor necrosis factor (TNF) inhibitors in dermatology, including pediatric psoriasis and hidradenitis suppurativa. New biosimilar TNF agents are in late stages of development and may be available in the United States in the near future. Biosimilar agents are similar but not identical to available TNF inhibitors, and approval requires extensive analytic, toxicity, pharmacokinetic, pharmacodynamic, and clinical testing. Semin Cutan Med Surg 35(supp6):S104-S106.
authors.affiliation: Assistant Professor of Dermatology Tufts University School of Medicine Director, Psoriasis Treatment Center SkinCare Physicians Chestnut Hill, Massachusetts.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Sobell
mesh_terms: D000328:Adult; D001685:Biological Factors / Q000627:therapeutic use; D002648:Child; D003879:Dermatologic Agents / Q000627:therapeutic use*; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D001685:Biological Factors; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha
keywords: Biosimilars; TNF inhibitors; hidradenitis suppurativa; pediatric psoriasis; psoriasis